ENB Therapeutics is a groundbreaking brand focused on overcoming immunotherapy resistance in cancer treatment. With a deep understanding of the tumor microenvironment, we have developed two unique mechanisms to target critical components and empower the body's immune system to effectively combat cancer. Our first approach involves developing small molecules that turn off a common switch called the ETBR, which activates pro-cancer components in the tumor microenvironment.

By doing so, we can transform cold tumors into hot tumors, allowing immune cells to infiltrate and kill tumors. Additionally, our therapies promote the formation of intratumoral TLOs, which are similar to lymph nodes and produce tumor-specific T- and B-cells. These TLOs act as antibody factories to induce long-lasting anti-cancer immunity.

Our products have shown promising preclinical efficacy in treating various forms of cancer, including melanoma, glioblastoma, squamous cell carcinoma, bladder cancer, and ovarian cancer. At ENB Therapeutics, we are dedicated to revolutionizing cancer therapy and providing solutions for drug-resistant cancers. Contact us to learn more about our innovative approach to tackling the challenges of immunotherapy resistance